{
  "module": "copd_repair_trial_design",
  "trial_id": "SEI-ITEPχ1-PH2",
  "blueprint_id": "ITEPEKIMAB-χ1",
  "phase": "Phase 2",
  "trial_design": "Stratified, randomized, adaptive, multi-arm",
  "enrollment_target": 100,
  "inclusion_model": "see sei_patient_logic_model.json",
  "arms": [
    {
      "arm_id": "A",
      "description": "IL-33-high + EDI-high (repair priority)",
      "dose": "Low-dose χ1 (25μg, inhaled weekly)",
      "allocation_ratio": 2,
      "expected_response": 0.82
    },
    {
      "arm_id": "B",
      "description": "IL-33-high + EDI-moderate",
      "dose": "Medium-dose χ1 (50μg, inhaled weekly)",
      "allocation_ratio": 1,
      "expected_response": 0.71
    },
    {
      "arm_id": "C",
      "description": "Control (inhaled placebo)",
      "dose": "0μg, matching vehicle",
      "allocation_ratio": 1,
      "expected_response": 0.22
    }
  ],
  "primary_endpoints": [
    {
      "label": "Annualized Rate of Moderate or Severe COPD Exacerbations",
      "type": "efficacy",
      "analysis": "Negative binomial regression",
      "success_threshold": "≥40% reduction vs. placebo, p < 0.05"
    }
  ],
  "secondary_endpoints": [
    {
      "label": "Entropy Score at Week 52",
      "type": "SEI-derived systemic stability metric",
      "target": "≤ 0.20"
    },
    {
      "label": "Lung Epithelial Integrity Score (LEIS)",
      "type": "composite biomarker panel",
      "target": "≥ 20% improvement from baseline"
    },
    {
      "label": "IL-1β / IL-17 Suppression Index",
      "type": "cytokine panel reduction",
      "target": "≥ 50% suppression from peak at Week 24"
    }
  ],
  "safety_monitoring": {
    "toxicity_tracking": true,
    "cytokine storm watch": true,
    "interim DSMB review": "Week 16 and 36"
  },
  "adaptive logic": {
    "interim_adjustment_allowed": true,
    "rules": [
      "Drop Arm B if Arm A ≥ 15% higher at Week 24",
      "Escalate Arm A dose only if LEIS plateau observed"
    ]
  },
  "trial_duration": "52 weeks + 8-week follow-up",
  "sei_oversight_enabled": true,
  "sei_trial_entropy_bound": "Class II (Low Entropy, Stable Progression)"
}
